Rituxan
information and resources from the National Cancer Institute
Rituximab Genentech, Inc Nov 26 1997
|
|
|
|
news articles
Tysabri poised for return to market 01 Apr 2006
Pharmaceutical Business Review Biogen Idec's Rituxan (rituximab) is another monoclonal antibody, while Acorda's Fampridine SR is a sustained release tablet that is in trials for both MS and ...
Rituxan Promising for Chronic Graft-versus-Host Disease Mar 24, 2006
MedPage Today, BOSTON, March 24 - For refractory chronic graft-versus-host disease (GvHD), Rituxan (rituximab) may offer a new option, according to the largest study to test ...
FDA Approves New Rituxan Use Mar 1, 2006
Red Herring, The US Food and Drug Administration has approved the drug Rituxan from Genentech and Biogen Idec for treating rheumatoid arthritis. ...
UPDATE 1-Genentech gets FDA OK for Rituxan for arthritis Feb 28, 2006
Reuters ...(BIIB.O: Quote, Profile, Research) on Tuesday said US regulators have approved their non-Hodgkin's lymphoma drug Rituxan as a treatment for rheumatoid arthritis ...
Genentech gets FDA OK for Rituxan for arthritis Feb 28, 2006
ABC News Inc. said on Tuesday US regulators have approved their non-Hodgkin's lymphoma drug Rituxan as a treatment for rheumatoid arthritis. ...
Cancer drug Rituxan receives federal approval to treat rheumatoid ... Mar 1, 2006
San Jose Mercury News, The Food and Drug Administration action comes more than eight years after the agency initially approved Rituxan to treat non-Hodgkin's lymphoma. ...
Rituxan Has Strong Potential Post-Approval Mar 1, 2006
Forbes Markets analyst Jason Kantor raised the target price on Biogen Idec to $54 from $41 following the US Food and Drug Administration's approval of Rituxan, a non ...
Rituxan's Expanded Use OKd Mar 1, 2006
Los Angeles Times, ...and Biogen Idec Inc. on Tuesday said US regulators had approved their non-Hodgkin's lymphoma drug Rituxan as a treatment for rheumatoid arthritis. ...
Genentech, Biogen get added Rituxan OK Mar 1, 2006
BusinessWeek ...and Biogen Idec Inc. said Wednesday that the Food and Drug Administration approved their drug Rituxan to help treat rheumatoid arthritis. ...
Rituxan Cleared for Rheumatoid Arthritis Mar 1, 2006
TheStreet.com Cramer's Take) and Biogen Idec (BIIB:Nasdaq - commentary - research - Cramer's Take) said the Food and Drug Administration approved Rituxan, in combination ...
FDA OKs new Rituxan use Feb 28, 2006
MarketWatch SAN FRANCISCO (MarketWatch) -- The Food and Drug Administration has approved Rituxan for patients with moderately-to-severely active rheumatoid arthritis who ...
FDA Approves Rituxan(R) - The First Targeted B-Cell Therapy for ... Feb 28, 2006
International News Service, ...announced today that the US Food and Drug Administration (FDA) has approved, following Priority Review, the therapeutic antibody Rituxan(R) (Rituximab) in ...
Genentech gets FDA OK for Rituxan for arthritis Mar 1, 2006
Brocktown News, NEW YORK - Genentech Inc (NYSE: - ) - ) said on Tuesday US regulators have approved their non-Hodgkin‘s lymphoma drug Rituxan as a treatment for rheumatoid ...
Future brighter for Rituxan Mar 2, 2006
Barre Montpelier Times Argus, The approval of the nation's top-selling cancer drug for a new use to treat rheumatoid arthritis could lead to further indications for Rituxan, which is being ...
Rituxan's potential grows Mar 2, 2006
Inside Bay Area, The approval of the nation's top-selling cancer drug as a new treatment for rheumatoid arthritis could lead to further uses for Rituxan, which is being studied ...
Genentech/Biogen Idec: Rituxan further expands its options Mar 2, 2006
Pharmaceutical Business Review Genentech and Biogen Idec's Rituxan has gained another FDA approval, making it the first selective B-cell therapy to be approved in rheumatoid arthritis. ...
Rituxan OK'd for Rheumatoid Arthritis Mar 1, 2006
WebMD ...arthritis (RA). Rituxan is recommended to treat moderate-to-severe rheumatoid arthritis in combination with methotrexate. It's specifically ...
FDA has approved Rituxan for treatment of moderate-to-severe ... Mar 1, 2006
Xagena.it, The FDA ( US Food and Drug Administration ) has approved the therapeutic antibody Rituxan ( Rituximab ) in combination with Methotrexate to reduce signs and ...
FDA Approves Rituxan for Refractory Rheumatoid Arthritis Mar 1, 2006
MedPage Today, ROCKVILLE, Md., March 1 - The FDA today approved Rituxan (rituximab), a therapy for non-Hodgkin's lymphoma, for treatment of rheumatoid arthritis. ...
Genentech's Rituxan given arthritis OK Mar 2, 2006
Pharmaceutical Business Review Following a priority review the FDA has granted approval to Genentech and Biogen Idec's therapeutic antibody Rituxan to be used in the treatment of rheumatoid ...
FDA APPROVES RITUXAN(R) (Rituximab), FIRST B-CELL TARGETED ... Mar 6, 2006
International News Service, NOW, THE US FDA HAS APPROVED RITUXAN TO TREAT PEOPLE WITH MODERATELY- TO SEVERELY-ACTIVE RA WHO HAVE INADEQUATELY RESPONDED TO TNF ANTAGONIST THERAPY. ...
Rituxan Approval In RA Can Benefit Lonza Mar 1, 2006
New Ratings 0959 GMT [Dow Jones] Roche (RHHBY), Genentech (DNA) getting approval for Rituxan in rheumatoid arthritis might bode well for Lonza (LONN.VX) which supplies the ...
Roche FDA OK On Rituxan A Catalytic Event Mar 1, 2006
New Ratings 1006 GMT [Dow Jones]--Roche (RHHBY) gaining FDA approval for Rituxan as a treatment for rheumatoid arthritis is a catalyst event, says Deutsche Bank, as "many ...
Pentostatin, Cyclophosphamide, Rituxan® Active in Chronic ... Mar 10, 2006
Cancer Consultants (press release), ...combination consisting of the chemotherapy agents pentostatin (Nipent®), cyclohpsophamide (Cytoxan®), and the biologic agent Rituxan® (rituximab) appears ...
Biogen Idec Faces Long-Term Growth Challenges Mar 31, 2006
Forbes Through 2009, Biogen (nasdaq: BGEN - news - people ) will see European royalties phase out for cancer drug Rituxan, marketed by Roche, along with decreased ...
Genentech, Biogen Idec Gain Approval Of Rituxan In RA Mar 1, 2006
BioWorld Online (subscription), By Aaron Lorenzo. The FDA approved Rituxan (rituximab) for rheumatoid arthritis, broadening the therapeutic antibody’s label and potentially its revenue. ...
FDA Approves First Rheumatoid Arthritis Ind ication for Rituxan ... Mar 1, 2006
PharmaLive.com (press release), ...that, after priority review, Genentech and Biogen Idec have received US approval for the first and only selective B-cell therapy Rituxan (rituximab, marketed ...
MultiVu Video Feed: FDA Approves Rituxan(R) - The First B-Cell ... Feb 28, 2006
PR Newswire (press release), The drug -- Rituxan -- treats RA in a new way by targeting immune cells called B-cells that may play multiple roles in this disease. ...
FDA clears Rituxan for rheumatoid arthritis Mar 1, 2006
Pharma Times (subscription), Genentech and Biogen Idec won approval to market their cancer drug Rituxan as a treatment for moderately-to-severely active rheumatoid arthritis yesterday, an ...
FDA APPROVES RITUXAN® - THE FIRST B-CELL TARGETED TREATMENT FOR ... Feb 28, 2006
PR Newswire (press release), The drug – Rituxan – treats RA in a new way by targeting immune cells called B-cells that may play multiple roles in this disease. ...
Pending Rituxan Arthritis Approval Means Little To Earnings Feb 27, 2006
Forbes Wachovia Securities maintained a "market perform" ratings on Genentech and Biogen Idec ahead of the action date for Rituxan expected tomorrow. ...
Genentech's Q1 Sales Of Herceptin Look Solid Mar 29, 2006
Forbes The company's top selling drug is Rituxan, a cancer drug that was also recently to treat rheumatoid arthritis, followed by Avastin and Herceptin. ...
FDA approves Rituxan (Rituximab) Mar 1, 2006
News-Medical.net, Idec announced today that the US Food and Drug Administration (FDA) has approved, following Priority Review, the therapeutic antibody Rituxan (Rituximab) in ...
FDA OKs Biogen’s use for Rituxan in rheumatoid arthritis Mar 1, 2006
Boston Mass High Tech, ...announced that the Food and Drug Administration has approved its therapeutic antibody Rituxan (rituximab) in combination with methotrexate to reduce signs and ...
Britain: Breast cancer patient’s legal challenge highlights ... Mar 30, 2006
Asian Tribune, Other cancer-fighting drugs such as Avastin, Erbitux, Gleevec, Rituxan and Tarceva are also increasingly deemed too expensive and are not currently widely ...
Genentech "outperform," estimates raised Mar 31, 2006
newratings.com 11. The analyst expects Genentech to post impressive results for the quarter on account of robust sales of Herceptin and Rituxan. ...
An infusion of new hope Mar 31, 2006
Globe and Mail, ...who wanted to remain anonymous -- gave her $5,000 to offset her expenses for the flight, hotel, associated travel costs and two doses of Rituxan, another drug ...
Genentech and Biogen Legal Troubles - When It Rains It Pours Mar 8, 2006
OpEdNews ...by Evelyn Pringle. Rituxan gained FDA approval in 1997, as a treatment for a certain type of non-Hodgkin's lymphoma. Roughly 12,760 ...
Off-label usage of drugs gets scrutinized Mar 3, 2006
San Diego Union Tribune, ...market. The Food and Drug Administration gave its approval Tuesday for the drug, Rituxan, to be used in treating rheumatoid arthritis. ...
Letter: Don't follow VA formula Mar 27, 2006
MetroWest Daily News, A few years ago, my uncle died from non-Hodgkin's lymphoma. He might be alive today if the break-through drug Rituxan had been on the Canadian formulary.
No Apologies for Genentech's Prices Mar 20, 2006
BusinessWeek One of your other big drugs is Rituxan, currently approved to treat non-Hodgkin's lymphoma. ... Rituxan does a very good job of helping those patients. ...
US gives a second life to a major cancer drug Mar 1, 2006
International Herald Tribune, NEW YORK Genentech and Biogen Idec have won US federal approval to sell their cancer drug Rituxan as a treatment for rheumatoid arthritis. ...
Rheumatoid Arthritis Drug Is Approved Feb 28, 2006
New York Times, Genentech and Biogen Idec won federal approval yesterday to sell their cancer drug Rituxan as a treatment for rheumatoid arthritis. ...
Cancer drug's approval as arthritis treatment lifts drug maker's ... Mar 1, 2006
Miami Herald, BOSTON - The approval of the nation's top-selling cancer drug as a new treatment for rheumatoid arthritis could lead to further uses for Rituxan, which is ...
Lymphoma drug FDA-approved for arthritis Mar 2, 2006
Cancerfacts.com, 1, 2006 – The FDA announced today that it has approved the cancer drug Rituxan® for treatment of patients with moderate-to-severe rheumatoid arthritis (RA ...
Tysabri Focus Obscures Another Biogen Idec Advance Mar 6, 2006
International News Service, But the Cambridge company is concerned that the focus on Tysabri is taking attention away from another one of its products, Rituxan. ...
Genentech Says 2006 Profit Will Rise as Much as 50% (Update2) Mar 17, 2006
Bloomberg Genentech said it expects the Rituxan cancer drug, approved for a new use March 1, and a blindness treatment that's under US Food and Drug Administration ...
Drug Gets New-Use Approval Feb 28, 2006
Washington Post, The drug, Rituxan, is among a new group of cancer treatments that are more precise and less toxic than older chemotherapy compounds. ...
Ailing woman is offered care Mar 17, 2006
Globe and Mail, The two doses of Rituxan she must use with it, however, will cost her just under $5,800, which she will pay through a line of credit. ...
Genentech expects 15 treatments in four years Mar 18, 2006
San Jose Mercury News, Genentech's Rituxan, which the FDA approved in 1997 for treating non-Hodgkin's lymphoma, generated $1.8 billion in US sales last year. ...
Roche Drug Approved for Rheumatoid Arthritis Mar 1, 2006
Smartmoney.com Wednesday has taken an important step in its bid to expand beyond its core oncology portfolio, gaining US regulatory approval for its main drug Rituxan as a ...
New Use for Cancer Drug OK'd Mar 1, 2006
CBS News ...(AP) The approval of the nation's top-selling cancer drug for a new use to treat rheumatoid arthritis could lead to further indications for Rituxan, which is ...
Genentech and Biogen Idec drug to be tested in diabetes Mar 17, 2006
Pharmaceutical Business Review Researchers at Indiana University School of Medicine are to test Genentech and Biogen Idec's Rituxan for its potential to help newly-diagnosed type 1 diabetics ...
Cancer Drug OK‘d As Arthritis Treatment Mar 2, 2006
Olberlin, BOSTON - The approval of the nation‘s top-selling cancer drug as a new treatment for rheumatoid arthritis could lead to further uses for Rituxan, which is ...
New Use for Cancer Drug OK‘d Mar 3, 2006
Herald News Daily, The approval of the nation‘s top-selling cancer drug for a new use to treat rheumatoid arthritis could lead to further indications for Rituxan, which is ...
Genentech's Pipeline Gap Seen Limiting Upside Mar 20, 2006
Forbes ...analyst noted that Genentech plans to move forward with its experimental drug, second-generation anti-CD20, the successor drug to cancer blockbuster Rituxan. ...
Genentech raises its goals for progress Mar 18, 2006
TheReporter.com, Should new uses be approved in the next four years for Rituxan, Herceptin, Avastin, or Xolair - the products manufactured for commercial use at the company's ...
Genentech "buy," target price raised Mar 20, 2006
newratings.com Genentech’s Herceptin, Avastin and Rituxan drugs are likely to be approved for additional indications going ahead, the analyst says. ...
Woman's last hope tied up in red tape Mar 16, 2006
Globe and Mail, A study of 143 patients assigned to two groups -- patients who received either Zevalin or Rituxan, a similar drug that fastens to the cancer cells and tags ...
FDA approves cancer drug for arthritis Mar 1, 2006
United Press International Rituxan, an expensive treatment for cancer but easier on the body than chemotherapy, can now be marketed to the often debilitating arthritis, The Washington ...
Arthritis Blog Archives Mar 2, 2006
About - News & Issues, Rituxan, the world's best-selling cancer drug has been FDA-approved to treat rheumatoid arthritis patients. ... Learn more about Rituxan. How is it administered? ...
Cancer drug to remedy arthritis Mar 3, 2006
Albuquerque Tribune, WASHINGTON - The nation's best-selling cancer drug, Rituxan, has won federal approval as a treatment for rheumatoid arthritis patients for whom other, older ...
TECH TICKER Mar 1, 2006
San Jose Mercury News, Genentech said Tuesday that it has won federal approval to use its cancer drug, Rituxan, as a treatment for some patients with arthritis. ...
Genentech, Biogen cancer drug approved for new indication Mar 2, 2006
New Ratings Genentech (DNA.NYS) and Biogen Idec (BIIB) Wednesday announced that the US Food & Drug Administration (FDA) had approved their cancer drug, Rituxan, for the ...
DAILY DIGEST Mar 1, 2006
San Francisco Chronicle, Genentech and Biogen Idec won federal approval on Tuesday to sell their cancer drug Rituxan as a treatment for rheumatoid arthritis. ...
Genentech Still 'Best Overall Story' In Biotech Mar 2, 2006
Forbes Bear Stearns maintained an "outperform" rating on Genentech after the US Food and Drug Administration approved Rituxan as a second-line treatment of rheumatoid ...
Roche poised to exploit new arthritis opportunity Mar 1, 2006
Reuters Regulators gave the green light on Tuesday for Roche's top-selling cancer drug, Rituxan or MabThera, to be used as a treatment for the crippling inflammatory ...
Biogen Idec says it's rebounding strongly Mar 13, 2006
Boston Globe, ...successes. Earlier this month, the FDA approved the company's Rituxan, a cancer drug, as a treatment for rheumatoid arthritis. A ...
Feds OK Cancer Drug For Rheumatoid Arthritis Mar 1, 2006
KETV.com, The Food and Drug Administration has approved Rituxan as a treatment for patients suffering from rheumatoid arthritis, biotech firms Genentech and Biogen said. ...
Cancer drug receives federal approval for rheumatoid arthritis Mar 1, 2006
KESQ, Biotech firms Genentech and Biogen say that the Food and Drug Administration has approved Rituxan as a treatment for patients suffering from rheumatoid ...
Roche Drug Approved for Rheumatoid Arthritis Mar 1, 2006
Smartmoney.com SAN FRANCISCO (Dow Jones) -- The Food and Drug Administration has approved Rituxan for patients with moderately-to-severely active rheumatoid arthritis who ...
FDA approves cancer drug to treat arthritis Mar 1, 2006
Standard-Speaker, The Food and Drug Administration action comes more than eight years after the agency initially approved Rituxan to treat non-Hodgkin’s lymphoma. ...
Genentech: Good Medicine Mar 1, 2006
Kiplinger.com, The company got two pieces of good news this week: The FDA said its lymphoma drug, Rituxan, could be used to treat certain cases of rheumatoid arthritis ...
Cancer Drug Approved for Rheumatoid Arthritis Mar 1, 2006
Forbes Rituxan (rituximab) targets immune cells known as CD20-positive B-cells, which are believed to contribute to rheumatoid arthritis (RA), according to a ...
Drug Stocks Tempered By Lofty Expectations Mar 4, 2006
Forbes ...nyse: DNA - news - people ) and Biogen Idec (nasdaq: BIIB - news - people ) received US Food and Drug Administration approval of blockbuster drug Rituxan as a ...
Cancer Drug Approved for Arthritis Sufferers Mar 2, 2006
WLNS, The FDA action comes more than eight years after the agency initially approved Rituxan to treat non-Hodgkin's Lymphoma. Rituxan ...
Cancer drug receives federal nod to treat rheumatoid arthritis Mar 1, 2006
Eyewitness News, The two companies said Rituxan should be used by patients who haven't had success with a class of rheumatoid arthritis drugs called tumor necrosis factor, or ...
(PRN) - Valmont Board Declares Quarterly Dividend ... [+] Feb 28, 2006
Bolsamania.com, ...(PRN) - MultiVu Video Feed: FDA Approves Rituxan(R) - The First B-Cell Targeted Treatment for Rheumatoid Arthritis ... [+. PRN) - BioMed ...
Genmab to receive $1 million milestone payment from Serono Feb 28, 2006
Pharmaceutical Business Review ...boasting about the potential of its arthritis treatment candidate HuMax-CD20, and the impact it could one day have upon Roche and Genentech's rival drug Rituxan ...
AbelsonTaylor Hires Two Mar 28, 2006
PharmaLive.com (press release), Brandi Homan, who joined the agency in January, will handle copywriting projects for Genentech Inc.’s Rituxan (rituximab), an agent for treating non-hodgkins ...
Playing Catch-up Mar 28, 2006
American Enterprise Institute, ...approved. Rituxan was originally approved for non-Hodgkin’s lymphoma but was recently approved for rheumatoid arthritis. Enbrel ...
RQ-PCR Positivity Predicts Relapse of Mantle Cell Lymphoma after ... Mar 9, 2006
Cancer Consultants (press release), Many chemotherapy agents, and specifically Rituxan® (rituximab), have shown activity against mantle cell lymphoma but have not improved overall average ...
PRESS DIGEST - Washington Post Business - March 1 Feb 28, 2006
Reuters The cancer drug Rituxan won federal approval to treat an entirely different disease, rheumatoid arthritis, in a development that doctors called a symbol of ...
Biovest International Submits Amendment Request To FDA For Use Of ... Feb 26, 2006
Medical News Today (press release), By contrast, Rituxan® (rituximab) a passive immunotherapeutic consisting of a monoclonal antibody, must be administered intravenously. ...
Genentech opens Louisville facility ahead of schedule Mar 6, 2006
Louisville Business First, ...of cancer and other medical needs. It makes the drugs Rituxan, Herceptin, Avastin, Xolair and others. In March 2005, the Kentucky ...
Lock In Roche Profits, Urges Dresdner Mar 1, 2006
New Ratings RHHBY) profits, says Dresdner Kleinwort Wasserstein, as stock is down around 2% year-to-date and should bounce Wednesday on news that Mabthera/Rituxan has been ...
Roche's US Mabthera OK Significant - ZKB Mar 1, 2006
New Ratings 0745 GMT [Dow Jones] Roche (RHHBY) gets FDA approval for Mabthera, known as Rituxan in the US, in rheumatoid arthritis. The move ...
Roche "sell" Mar 1, 2006
New Ratings ...note published this morning, the analysts mention that the company’s share price is expected to appreciate today due to the approval of Rituxan for the ...
Arthritis Foundation Statement on Rituximab for Rheumatoid ... Mar 1, 2006
U.S. Newswire (press release), The US Food and Drug Administration's (FDA) approval of rituximab (Rituxan(r)) in combination with methotrexate to reduce the signs and symptoms of rheumatoid ...
Midday Business Report: O’Reilly jumps on earnings report Mar 1, 2006
Kansas City Star, ...said today. The Food and Drug Administration action comes more than eight years after the agency initially approved Rituxan to treat non-Hodgkin’s lymphoma. ...
Genentech Boosts Earnings Forecast; Shares Rise Mar 18, 2006
Los Angeles Times, The non-Hodgkin's lymphoma drug Rituxan, which recently won approval for rheumatoid arthritis, will also be studied in lupus, multiple sclerosis and Type 1 ...
Roche stock rises after Genentech ups forecasts Mar 20, 2006
Reuters ...its forecasts for shipments to its partners to "up to 20 percent over 2005" from flat, suggesting that Roche's sales in Europe of Rituxan/Mabthera and Avastin ...
Cancer drugs can top $100,000 a year Mar 19, 2006
Chicago Sun-Times, ERBITUX (Colorectal and head-and-neck cancers): $9,800 per month. RITUXAN (Non-Hodgkin's lymphoma): $13,000 to $25,000 per treatment cycle. ...
Genentech raises EPS forecast, approvals target Mar 17, 2006
MSN Money It will also study non-Hodgkin's lymphoma drug Rituxan, which recently won approval for rheumatoid arthritis, lupus, multiple sclerosis and Type 1 diabetes. ...
Genentech stock jumps on earnings projection Mar 17, 2006
CNNMoney.com The company's top-selling drug, Rituxan, a treatment for rheumatoid arthritis and non-Hodgkin's lymphoma, totaled $1.8 billion in US sales in 2005. ...
Genentech "outperform" Mar 21, 2006
newratings.com The company's plans to expand the indications for Rituxan and Avastin offer near- and long-term revenue growth opportunities, the analyst says.
TeGenero Mab causes shock side-effects in UK trial Mar 17, 2006
Pharmaceutical Business Review Humira (adalimumab), which generated global sales of $1.4 billion in 2005, and Roche, Genentech and Biogen Idec's leukemia treatment Rituxan/MabThara (rituximab ...
Biotechs may be a good bet for 2006 21 Dec 2005
CNN It has three top products: Rituxan and Herceptin, both breast cancer treatments for specific genes; and Avastin, a treatment for colorectal cancer. ...
Reasonable premium 21 Dec 2005
Reuters Although the growth rate for sales of cancer product Rituxan was lower than for some of DNA's other products (up 16%), it is important to keep in mind that ...
Rituxan® and CHOP for Elderly Patients with Diffuse Large B-Cell ... Dec 19, 2005
Cancer Consultants (press release), Researchers in Germany have reported that six cycles of Rituxan® (rituximab) and CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), given ...
Rituxan® is an Effective for “Purging� of Stem Cell Grafts ... Dec 15, 2005
Cancer Consultants (press release), Researchers from Case Western Reserve and Cancer Center have reported that in-vivo purging with Rituxan® (rituximab) is effective as or more effective than ex ...
Maintenance therapy with RITUXAN(R) dramatically improves survival Dec 12, 2005
CNW Telbec (Communiqués de presse), 12 /CNW/ - Two years of maintenance therapy with Rituxan (rituximab) dramatically improves the chances of survival for patients suffering from one of the most ...
Pilot Clinical Study of Genasense (oblimersen sodium) Plus Rituxan ... Dec 12, 2005
DG News ...the use of its lead anticancer compound, Genasense(R) (oblimersen sodium) Injection, in combination with fludarabine plus rituximab (Rituxan(R); Genentech/IDEC ...
Blockbuster Drugs Rituxan, Avastin, and Erbitux Changes the Way ... Dec 5, 2005
Genetic Engineering News, The blockbuster drugs Rituxan, Avastin, and Erbitux have changed the way the industry looks upon antibody treatment of cancer in the same way that Taxol ...
Rituxan® Plus CHOP Improves Outcomes of Patients with Follicular ... Nov 22, 2005
Cancer Consultants (press release), Researchers from Germany have reported that adding Rituxan (rituximab) to CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) improves outcomes of ...
Nipent®/Cytoxan®/Rituxan® Shows High Activity in High-Risk ... Nov 23, 2005
Cancer Consultants (press release), Mayo Clinical have reported that the treatment combination consisting of Nipent (pentostatin), Cytoxan (cyclophosphamide) and Rituxan (rituximab) demonstrates ...
ACR Rituxan Shows Durable Response for Refractory RA Nov 18, 2005
MedPage Today, 18 - Rheumatoid arthritis patients who get no relief from DMARDs -- such as Remicade, Enbrel, or Humira -- may benefit from Rituxan (rituximab), a B-cell ...
ASH: Experimental Chemotherapy Drug Effective Against Resistant ... Dec 14, 2005
MedPage Today, In a Phase 2 study of monotherapy with Treanda for 77 patients with relapsed indolent or transformed Rituxan (rituximab)-refractory B-cell NHL, 35% had a ...
Combo therapy effective for NHL Dec 15, 2005
myDNA.com, A new trial looking at patients with follicular B-cell non-Hodgkin's lymphoma (NHL) finds that the drug Rituxan (rituximab), followed by a vaccination with an ...
Favrille Reports Positive Data from Phase 2 Clinical Trial of ... Dec 13, 2005
PR Newswire (press release), ...for the treatment of cancer, reported positive long-term follow-up data from its Phase 2 clinical trial of FavId(R) following Rituxan(R) treatment in patients ...
Favrille Reports Positive Data from Phase 2 Clinical Trial of ... Dec 13, 2005
DG News ...reported positive long-term follow-up data from its phase 2 clinical trial of FavId(R) following Rituxan(R) treatment in patients with follicular B-cell non ...
Pharmacyclics' Stock Crushed After Failed Phase III Of Xcytrin Dec 19, 2005
BioWorld Online (subscription), ...when given in combination with Zevalin (ibritumomab tiuxetan), was well tolerated and had synergistic activity in patients with Rituxan (rituximab)-refractory ...
Pharmacyclics Announces Presentation and Publication of ... Dec 12, 2005
Yahoo! News (press release) ...in combination with Zevalin® (Ibritumomab Tiuxetan), is well-tolerated and demonstrates synergistic activity in patients with Rituxan® (rituximab)-refractory ...
Pharmacyclics Announces Presentation and Publication of ... Dec 12, 2005
PharmaLive.com (press release), ...when given in combination with Zevalin(R) (Ibritumomab Tiuxetan), is well-tolerated and demonstrates synergistic activity in patients with Rituxan(R) (rituximab ...
Favrille Announces Appointment of David Guy as Chief Commercial ... Dec 5, 2005
PharmaLive.com (press release), ...of Favrille's lead product candidate, FavId(R). FavId is nearing completion of enrollment in a pivotal Phase 3 clinical trial following Rituxan(R) treatment in ...
R-CHOP Improves Outcomes as Initial Therapy in Follicular Lymphoma Nov 28, 2005
Cancer Consultants (press release), According to a recent article published in the journal Blood, the addition of Rituxan® (rituximab) to the chemotherapy combination referred to as CHOP ...
Favrille: FavId Improves Cancer Drugs Dec 13, 2005
MSN Money Mid-stage clinical trial data showed the company's FavId treatment increased the clinical response rate to the cancer therapy Rituxan to 65 percent from 49 ...
Genentech "overweight" Dec 13, 2005
New Ratings In a research note published yesterday, the analyst mentions that data from the E1496 study is expected to support the usage of the company’s Rituxan drug in ...
Roche's MabThera Sales Upside Seen Dec 13, 2005
New Ratings ..."We estimate that this indication could result in a potential $2.5B upside to our 2010 global Rituxan sales forecast in NHL of $4.8B." MabThera, known as ...
ATLANTA -- Abstracts Presented at 2005 ASH Annual Meeting Reveal ... Dec 14, 2005
dBusinessNews Atlanta (press release), ...respectively. Infusion-related toxicities were typically grade 1 or 2 and were associated with pre-administration of rituximab (RITUXAN). ...
Favrille Announces Appointment of David Guy as Chief Commercial ... Dec 5, 2005
Yahoo! News (press release) FavId is nearing completion of enrollment in a pivotal Phase 3 clinical trial following Rituxan® treatment in patients with follicular B-cell non-Hodgkin's ...
Adding Radioimmunotherapy To Chemotherapy Reduces Relapse Risk In ... Dec 17, 2005
Medical News Today (press release), ...in one study more than 90 percent of patients responded to a combination of chemotherapeutic drugs plus a monoclonal antibody (CHOP and Rituxan®), but the ...
Genentech initiated with "overweight" Dec 7, 2005
New Ratings ...s top-line is likely to be driven in the near future by continued label expansion of the company’s key products, Avastin, Herceptin and Rituxan, the analyst ... |
